Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(16):1359-1360; doi:10.1093/jnci/91.16.1359
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Volkers, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Volkers, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 16, 1359-1360, August 18, 1999
© 1999 Oxford University Press

NEWS

Making Sense: Therapy Targeting RNA Continues to Advance

Nancy Volkers

In retrospect, the concept of antisense seems startlingly simple.

Find a protein that's essential to cancer cells, create a single-stranded sequence of nucleotides complementary to a part of the RNA from which the protein arises, and then send in a complementary sequence to "tie up" the RNA — thus preventing protein production and stopping tumors cold.

Antisense research is not limited to cancer. In fact, the U.S. Food and Drug Administration recently approved the first antisense drug, fomavirsen (Vitravene®), for retinitis induced by cytomegalovirus. The drug, a product of ISIS Pharmaceuticals Inc., . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?